Committee for Orphan Medicinal Products
The Committee for Orphan Medicinal Products (COMP) is the European Medicines Agency's scientific committee responsible for the scientific evaluation of applications for Orphan Drug Status. During its development, a medicinal product can already receive the designation "Orphan Drug Status" which then has to be confirmed at granting of the marketing authorisation.
The Committee for Orphan Medicinal Products consists of scientific experts from all Member States of the EEA including representatives of patients and healthcare professionals. For further information on the Committee for Orphan Medicinal Products please visit the European Medicines Agency's website. A list of all medicinal products with the Orphan Drug Status can be found in the European Commission's Community Register of orphan medicinal products for human use.